Johnson & Johnson (NYSE:JNJ) Shares Sold by Cascade Investment Group Inc.

Cascade Investment Group Inc. lessened its stake in Johnson & Johnson (NYSE:JNJ) by 7.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,717 shares of the company’s stock after selling 226 shares during the period. Cascade Investment Group Inc.’s holdings in Johnson & Johnson were worth $393,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. IFS Advisors LLC increased its stake in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $31,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares during the period. Finally, Activest Wealth Management acquired a new position in Johnson & Johnson during the third quarter worth $40,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Guggenheim upped their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Bank of America reduced their price objective on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a report on Friday, January 17th. Finally, Morgan Stanley raised their price target on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Hold” and an average target price of $173.27.

Johnson & Johnson Stock Up 0.7 %

Shares of NYSE JNJ opened at $148.10 on Wednesday. The firm has a market cap of $356.57 billion, a P/E ratio of 21.43, a price-to-earnings-growth ratio of 2.39 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The firm’s 50 day moving average price is $148.35 and its 200 day moving average price is $156.11.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.35%. Johnson & Johnson’s payout ratio is currently 71.78%.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.